G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β-Catenin and Cancer Research

Executive Summary: G007-LK is a highly selective small-molecule inhibitor of tankyrase 1 and 2 (TNKS1/2), enzymes implicated in Wnt/β-catenin signaling, cellular proliferation, and oncogenesis [Jia et al., 2017]. In vitro, G007-LK inhibits auto-poly(ADP-ribosyl)ation of TNKS1/2 with nanomolar potency (IC50 46 nM and 25 nM, respectively) [APExBIO]. In APC-mutant colorectal and hepatocellular carcinoma models, it drives β-catenin degradation and AXIN1/2 stabilization, resulting in suppressed tumor cell growth [Jia et al., 2017]. G007-LK also downregulates YAP/TAZ signaling by stabilizing AMOTL1/2, expanding its utility to Hippo pathway research [Jia et al., 2017]. The compound is commercially available from APExBIO as SKU B5830 and is validated for use in diverse cancer biology workflows [APExBIO].

Biological Rationale

Tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2) are poly(ADP-ribose) polymerases (PARPs) that regulate protein stability and signaling networks, including the Wnt/β-catenin and Hippo pathways [Jia et al., 2017]. Aberrant activation of Wnt/β-catenin signaling is a hallmark of many cancers, particularly those with APC mutations such as colorectal carcinoma [Related Article]. Tankyrases promote β-catenin stabilization by mediating poly(ADP-ribosyl)ation and subsequent degradation of AXIN, a negative regulator of Wnt signaling. Inhibiting tankyrase activity preserves AXIN1/2, facilitates β-catenin degradation, and suppresses oncogenic transcriptional programs [Jia et al., 2017]. YAP/TAZ, effectors of the Hippo pathway, are also modulated by tankyrase-mediated turnover of AMOTL1/2, linking tankyrase function to multiple growth-regulatory circuits.

Mechanism of Action of G007-LK Tankyrase 1/2 Inhibitor

G007-LK is a small-molecule inhibitor with high selectivity for TNKS1 and TNKS2. It binds to the catalytic PARP domain, inhibiting auto-poly(ADP-ribosyl)ation and enzymatic activity. This inhibition stabilizes AXIN1/2 and AMOTL1/2 by blocking their tankyrase-mediated degradation. As a result, G007-LK promotes β-catenin ubiquitination and proteasomal degradation, thereby reducing cytosolic and nuclear β-catenin levels. In Wnt3a-stimulated HEK 293 cells, G007-LK inhibits the Wnt signaling reporter (ST-Luc) with an IC50 of 0.05 μM. In APC-mutant colorectal cancer cell lines (e.g., SW480), the inhibitor induces the formation of β-catenin degradasomes and reduces oncogenic signaling. G007-LK also downregulates YAP by stabilizing AMOTL1/2, linking tankyrase inhibition to Hippo pathway suppression [Jia et al., 2017].

Evidence & Benchmarks

• G007-LK inhibits TNKS1 and TNKS2 auto-poly(ADP-ribosyl)ation in vitro with IC50 values of 46 nM and 25 nM, respectively (APExBIO).
• Reduces Wnt/β-catenin signaling in Wnt3a-induced HEK 293 cells with a reporter IC50 of 0.05 μM (APExBIO).
• Induces β-catenin degradasome formation and decreases cytosolic/nuclear β-catenin in APC-mutant colorectal cancer cells (Related Article).
• Suppresses proliferation of hepatocellular carcinoma (HCC) cell lines in a dose-dependent manner (Jia et al., 2017).
• Synergizes with MEK and AKT inhibitors to further inhibit HCC cell proliferation (Jia et al., 2017).
• Downregulates YAP/TEAD luciferase reporter activity and decreases YAP protein levels via AMOTL1/2 stabilization (Jia et al., 2017).
• Demonstrates antitumor efficacy in COLO-320DM xenograft mouse models, reducing TNKS1/2 and β-catenin protein levels in vivo (APExBIO).

This article updates and extends the mechanistic focus provided in 'G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β...' by integrating recent in vivo validation and quantifying Hippo pathway effects. For a guide on assay integration and troubleshooting, see 'Reliable Pathway Control...'.

Applications, Limits & Misconceptions

G007-LK is primarily used for:

• Investigating Wnt/β-catenin pathway inhibition in APC-mutant colorectal cancer and hepatocellular carcinoma models.
• Studying β-catenin degradation and AXIN1/2 stabilization.
• Probing Hippo pathway regulation via YAP/TAZ and AMOTL1/2.
• Exploring tankyrase function in cell cycle, telomere homeostasis, and protein turnover.
• Preclinical validation of combination therapies (e.g., with MEK/AKT inhibitors).

Limitations include poor aqueous and ethanol solubility, necessitating use of DMSO (≥26.5 mg/mL). G007-LK is not suitable for direct in vivo systemic administration without formulation optimization. Its effects are context-dependent and may vary with cell line genotype, especially outside APC-mutant or Wnt-dependent models. For expanded discussion on translational scenarios and caveats, compare with 'Expanding Horizons in β-...', which this article clarifies by detailing workflow parameters and storage stability.

Common Pitfalls or Misconceptions

• G007-LK is not a pan-PARP inhibitor; it is selective for tankyrase 1/2 and does not broadly inhibit other PARP family members.
• It does not directly inhibit β-catenin but acts upstream by stabilizing AXIN1/2 and AMOTL1/2.
• Insoluble in water and ethanol—incorrect solvents can lead to precipitation or inconsistent dosing.
• Long-term solutions are unstable; store as solid at -20°C and prepare fresh solutions for use.
• Efficacy is reduced in Wnt-independent or tankyrase-insensitive cell models.

Workflow Integration & Parameters

For optimal use of G007-LK (APExBIO SKU B5830), dissolve in DMSO to obtain stock solutions (≥26.5 mg/mL). For complete dissolution, warm to 37°C or use an ultrasonic bath. Avoid water or ethanol as solvents. Store solid at -20°C and avoid long-term solution storage. In cell-based assays (e.g., Wnt3a-induced HEK 293 or APC-mutant SW480), effective concentrations range from 0.025–1 μM, with observed IC50 values of 0.05 μM for Wnt reporter inhibition. In vivo, G007-LK demonstrates efficacy in xenograft models with appropriate vehicle formulation. For protocol integration, see the workflow guide in 'Optimizing Wnt/β-Catenin...'; this article provides updated solvent compatibility and stability data.

Conclusion & Outlook

G007-LK tankyrase 1/2 inhibitor is a validated, mechanistically precise tool for dissecting Wnt/β-catenin and Hippo signaling in cancer models. Its nanomolar potency, selective mechanism, and reproducible in vitro and in vivo benchmarks make it central to APC mutation colorectal and hepatocellular carcinoma research. Ongoing studies continue to define its role in combination therapies and non-canonical signaling networks. For product acquisition and full specifications, refer to the G007-LK tankyrase 1/2 inhibitor product page from APExBIO.